INmune Bio
Business Services · Florida, United States · <25 Employees
Who is INmune Bio
INmuneBio,Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is in clinical trial to determine if it can treat cancer (INB03™), Mild Alzheimer's disease, Mild Cognitive Impairment and treatment resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient's NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio's product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation.Read More
Headquarters:
225 NE Mizner Blvd, Suite 640, Boca Raton, Florida, 33432, United States
Revenue:
<$5 Million
Stock Symbol:
INMB
INmune Bio's Social Media
Popular Searches:
INmune Bio Inc
Inmune Bio , Inc.
INmune Bio Inc.
INmune Bio
INmune Bio, Inc.
Top Competitors of INmune Bio
INmune Bio's Org Chart
INmune Bio's Tech Stack
INmune Bio News & Media
USPTO Issues Patent Covering Use of XPro™ for Treatment of CNS Diseases
Boca Raton, Florida, June 22, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announces the issuance of U.S. Pat. No. 11,365,229 for “METHODS OF TREATING NEUROLOGICAL DISEASES,” a patent directed to use of Dominant Negative Tumor Necrosis Factor (DN-TNF) variants, such as the Company’s XPro™, by peripheral administration for crossing the
Jun 22, 2022
INmune Bio, Inc. Presents Data on Combination Therapy with INB03™ on Overcoming Resistance to HER2 Targeted Therapies in Breast Cancer
In pre-clinical models of trastuzumab resistant MUC4 HER2+ breast cancer, treatment with INB03™ decreases MUC4 expression, reverses resistance to trastuzumab based therapies, and promotes an immunologically active TME.Jun 16, 2022
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of INmune Bio, Inc. - INMB
New York, New York--(Newsfile Corp. - June 15, 2022) - Pomerantz LLP is investigating claims on behalf of investors of INmune Bio, Inc. ("INmune" or the "Company") (NASDAQ: INMB). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether INmune and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...Jun 15, 2022Subscribe to "INmune Bio" News
Frequently Asked Questions regarding INmune Bio
Where are INmune Bio’s headquarters?
INmune Bio’s headquarters are in 225 NE Mizner Blvd, Suite 640, Boca Raton, Florida, 33432, United States
What is INmune Bio’s stock symbol?
INmune Bio’s stock symbol is INMB
What is INmune Bio’s official website?
INmune Bio’s official website is www.inmunebio.com
What is INmune Bio’s Revenue?
INmune Bio’s revenue is <$5 Million
What is INmune Bio’s SIC code?
INmune Bio’s SIC: 28,283
What is INmune Bio’s NAICS code?
INmune Bio’s NAICS: 3254,541714
How many employees are working in INmune Bio?
INmune Bio has <25 employees
What is INmune Bio’s industry?
INmune Bio is in the industry of: Business Services, Research & Development, Manufacturing
Who are INmune Bio’s main competitors?
INmune Bio's main competitors are: Nantkwest, Checkmate Pharmaceuticals, Targovax, Leap Therapeutics
What is INmune Bio's tech stack?
The technologies that are used by INmune Bio are: ASP.NET, Google Website Translator, Font Awesome, GTranslate
Test Drive ZoomInfo's Directories
Browse Directories
